ReviewJournal of neurology2011
Managing MS in a changing treatment landscape.
Review in Journal of neurology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 29 citations in OpenAlex.
- Long-term disability outcomes in relapsing-remitting multiple sclerosis: a 10-year follow-up study.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2019Observational
- A survey of risk tolerance to multiple sclerosis therapies.Neurology · 2019Article
- Predictors for Therapy Response to Intrathecal Corticosteroid Therapy in Multiple Sclerosis.Frontiers in neurology · 2019Article
- Cladribine tablets' potential role as a key example of selective immune reconstitution therapy in multiple sclerosis.Degenerative neurological and neuromuscular disease · 2018Review
- Effect of Chronic Medical Conditions in Veterans with Multiple Sclerosis on Long-Term Disability.Medical science monitor : international medical journal of experimental and clinical research · 2016Observational
- Induction of oligodendrocyte differentiation and in vitro myelination by inhibition of rho-associated kinase.ASN neuro · 2014Article
- Progress in multiple sclerosis research in the last year.Journal of neurology · 2012Article
- Single nucleotide polymorphisms in multiple sclerosis: disease susceptibility and treatment response biomarkers.Immunologic research · 2012Review
- Chronic cladribine administration increases amyloid beta peptide generation and plaque burden in mice.PloS one · 2012Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 8 institutions in 7 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Increasing options are dictating the development of new algorithms to provide guidance in the treatment of people with multiple sclerosis (MS). There is a wealth of evidence on the safety and efficacy of interferon-beta and glatiramer acetate, which have been used in Europe and in the United States for more than 10 years. The spectrum of approved indications for these conventional disease modifying therapies includes the treatment of relapsing-remitting MS, secondary progressive MS, and the clinically isolated syndrome. Beyond these therapies we already have the recently introduced antibody natalizumab and, in some countries, the immunosuppressive agent mitoxantrone. Oral therapies are expected in the near future, with the sphingosin-1-phosphate receptor modulator fingolimod approved in the US and the EU and the purine nucleoside analogue cladribine in Australia and Russia. The evidence on all of these conventional and novel therapeutics is reviewed in this paper to provide an overview of the changing landscape of MS treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.